Details of the Drug

General Information of Drug (ID: DMUMOEV)

Drug Name

Ansuvimab

Indication

Disease Entry	ICD 11	Status	REF
Ebola virus infection	1D60.0	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Zaire ebolavirus (strain Mayinga-76)

ATC Code

J06BD04: Ansuvimab

J06BD: Antiviral monoclonal antibodies

J06B: IMMUNOGLOBULINS

J06: IMMUNE SERA AND IMMUNOGLOBULINS

J: ANTIINFECTIVES FOR SYSTEMIC USE

Drug Type

Antibody

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 1480 +/- 304 mgday/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 198.45 +/- 45.15 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.21 +/- 1.56 h [2]
Clearance: The clearance of drug is 115 +/- 15 mL/day [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 20.1 +/- 6.9 days (a single adminutesistration of 5 mg/kg), and 26.7 +/- 3.8 (a single adminutesistration of 10 mg/kg) [2]
Metabolism: The drug is metabolized via various proteolytic and catabolic processes within the body []
Vd: The volume of distribution (Vd) of drug is 5.08 +/- 0.88 L [2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ebola virus Envelope glycoprotein (EV GP)	TT2F0AU	VGP_EBOZM	Not Available	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.